NCT07234292 Evaluation of Patient Satisfaction With Blephaderm as a Complementary Care in Post-eyelid Surgery

Eligibility & Interventions

Eligibility Fast-Check

Enter your details for a quick preliminary check. This does not replace medical advice.

What to Expect as a Participant

This is an observational study. You will not receive an experimental treatment; researchers will collect data based on your existing condition or standard treatment.

This trial targets 30 participants in total. It began in 2025-10-30 with a primary completion date of 2026-12-15.

Brief Summary

The goal of this non-interventional, open and monocentric study is to evaluate the satisfaction of 30 patients, after 3 months with Blephaderm eyelid cream, as a complementary care in post-eyelid surgery (Blepharopasty or ptosis). The participant will be asked to use Blephaderm twice a day. The patient satisfaction will be evaluated using a VAS scale.

Eligibility Criteria

Inclusion Criteria: * Age ≥ 18 years old * Patients planning a blepharoplasty or a ptosis surgery in at least one eye. * Patient affiliated to a health social security system * Female of childbearing potential should use a medically accepted contraceptive regimen since at least 12 weeks before the beginning of the study, during all the study and at least 1 month after the study end. Exclusion Criteria: In terms of population: * Pregnant or nursing woman or planning a pregnancy during the study. * Patient who had been deprived of their freedom by administrative or legal decision * Minor patient. * Major patient who is under guardianship or who is not able to express his non opposition. * Patient suspected to be non-compliant according to the investigator's judgment. * Patient enrolled in another clinical trial or which exclusion period is not over. In terms of associated pathology * Patient with a history or active systemic condition or receiving a medication which, in the investigator's judgment, put the patient at undue risk. * Patient suffering from a severe or progressive disease. * Patient with known or suspected hypersensitivity to one of the components of the product. Related to previous or ongoing treatment * Patient undergoing a topical treatment on the test area or a systemic treatment. * Patient under a long-term corticosteroid, NSAID or HIV therapy at the investigator appreciation. * Patient under immunosuppressive therapy * Patient under bisphosphonate therapy * Patient having Type 1 diabetes * Patient having atopic or eczema skin In terms of lifestyle * Intensive exposure to sunlight or UV-rays foreseen during the study. * Patient planning to change her/his life habits during the study. * Patient with an excessive consumption of alcohol and/or tobacco defined as: * an excessive consumption of alcohol: Drinking more than * 4 units a day for adult men and more than 2 units a day for adult women, * an excessive consumption of tobacco: ≥15-20 Cigarettes Per Day (CPD).

Contact & Investigator

Frequently Asked Questions

Related Trials